Table 2.
Multiply TLRa in combination with nanoparticles.
| Nanoparticles | Sub Classses | TLRa | Immunoadjuvants | Administration Route | Tumor Model | References |
|---|---|---|---|---|---|---|
| phospholipid micelles loaded with zinc-doped iron oxide magnetic nanoparticles (MNPs) | TLR3, TLR7 | Poly(I:C), R837 | ovalbumin | subcutaneous | B16-F10 | [114] |
| liposomes | TLR3, TLR9 | Poly(I:C), CpG-ODN | ovalbumin | intraperitoneal | EL4 | [115] |
| PCL−PEG-PCL & DOTAP(IMNPs) & DSPE-PEG-mannose (MAN-IMNPS)lipid-polymer hybrid nanoparticles |
TLR4, TLR7/8 | MPLA, R837 | ovalbumin, anti-PD-1 | subcutaneous | E.G7-OVA | [43] |
| mannose-functionalized lipid-hybrid polymersomes (MAN-IMO-PS) | TLR4, TLR7/8 | MPLA, R837 | ovalbumin | intramuscular | E.G7-OVA | [117] |
| the lipids shell POPC/DMPG, PLGA of PEGylated-coated nanoparticles (NPs) | TLR4, TLR9 | MPLA, CpG | α-galactosylceramide (GalCer), melanoma antigens |
subcutaneous | B16-F10 | [118] |
| mesoporous silicon vector (MSV) microparticles | TLR4, TLR9 | MPLA, CpG | tyrosinase related protein 2 (TRP2) peptide | intravenous | B16 | [119] |
| sHDL nanodiscs(ND) | TLR4, TLR9 | MPLA, CpG | ovalbumin, E7 peptide antigen | subcutaneous | B16F10-OVA, TC-1 | [120] |
| PLGA/PEI NPs | TLR9 + TLR4 or TLR7/8 | CpG ODN, MPLA or R848 | N/A | subcutaneous | J774 | [116] |
| BanNVs | TLR7/8, TLR9 | R848, CpG-ODNs | Adpgk, aPD-1 | subcutaneous | MC38 | [121] |